Analyst Price Target is $3.50
▲ +422.47% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Bolt Biotherapeutics in the last 3 months. The average price target is $3.50, with a high forecast of $8.00 and a low forecast of $1.00. The average price target represents a 422.47% upside from the last price of $0.67.
Current Consensus is
Hold
The current consensus among 5 contributing investment analysts is to hold stock in Bolt Biotherapeutics. This Hold consensus rating has held steady for over two years.
Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-3042, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.
Read More
